Lim, Ru Sin, Chung, Yue Ling, Biros, Erik, Harris, Trudie, Fowles, Lindsay, Patel, Chirag, Scuderi, Carla, Tchan, Michel, Rangan, Gopala, Mallawaarachchi, Amali, Faull, Randall, Huntley, Vanessa, and Mallett, Andrew J. (2025) A Pilot Study of Pharmacogenomics in Patients With Kidney Failure of an Unknown Cause. Kidney International Reports, 10. pp. 4065-4068.

Preview

PDF (Published Version) - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (1MB) | Preview

Abstract

[Extract] Chronic kidney disease (CKD) affects about 850 million people worldwide and is a leading cause of illness and death.1 Patients with advanced CKD, especially in stage 5, face higher risks of drug toxicities and reduced treatment effectiveness because of impaired kidney clearance, multiple medications, various comorbidities, and uremic toxins that influence drug behavior.2 Improving pharmacological treatment for this high-risk group is crucial to lowering mortality and morbidity. Pharmacogenomic analysis, which identifies genetic differences in drug-metabolizing enzymes, transporters, and receptors, offers a promising approach to personalizing therapy and improving outcomes in CKD. This pilot study examines the prevalence of common actionable pharmacogenomic variants in patients diagnosed with stage 5 CKD, using whole genome sequencing data from the HIDDEN study, which mainly investigates genetic causes of CKD of unknown cause.3

Actions (Repository Staff Only)

Item Control Page